MBIO - Mustang Bio Inc

-

$undefined

N/A

(N/A)

Mustang Bio Inc NasdaqCM:MBIO Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

Location: 95 Sawyer Road, Waltham, MA, 02453, United States | Website: https://www.mustangbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-8.365M

Cash

14.23M

Avg Qtr Burn

-1.87M

Short % of Float

2.14%

Insider Ownership

10.94%

Institutional Own.

6.88%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
MB-107 Details
X-Linked severe combined immunodeficiency

Phase 2

Update

MB-207 Details
X-Linked severe combined immunodeficiency, Myelofibrosis

Phase 2

Update

MB-106 (CD20) (Mustang Multicenter) Details
Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Cancer, Lymphoma

Phase 2

Initiation

MB-106 (CD20) (Fred Hutch) Details
Lymphoma, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Epstein-Barr virus, Multiple sclerosis, Cancer, Waldenstrom macroglobulinemia

Phase 1/2

Update

MB-101 (IL-13Ra2) + MB-108 Details
Medulloblastoma, Ependymoma, Glioblastoma, Leptomeningeal brain tumors

Phase 1

Initiation

MB-104 Details
Multiple myeloma, Cancer, Solid tumor/s

Failed

Discontinued

MB-102 (CD123) Details
High risk myelodysplastic syndromes , Blastic plasmacytoid dendritic cell neoplasm, Acute myeloid leukemia, Cancer

Failed

Discontinued

MB-110 (LV-RAG1) Details
Severe combined immunodeficiency due to complete RAG1/2 deficiency

Failed

Discontinued

MB-105 (PSCA) Details
Prostate cancer, Multiple myeloma, Cancer

Failed

Discontinued

MB-103 (HER2) Details
Glioblastoma, Metastatic breast cancer to brain, Cancer

Failed

Discontinued